Listen to the article
Trump Dismisses Reports of Potential FDA Commissioner Firing
President Donald Trump downplayed reports that he intends to remove Food and Drug Administration Commissioner Marty Makary from his position, telling reporters on Friday that he “knows nothing about it” despite widespread speculation in Washington.
“I’ve been reading about it, but I know nothing about it,” Trump said when questioned about Makary’s potential dismissal. When pressed further about what might be happening with the FDA chief, Trump simply responded, “nothing much.”
The speculation began earlier this week when The Wall Street Journal reported that Trump had pressured Makary to expedite approval for flavored nicotine vapes, a request that reportedly met with resistance from the commissioner. According to follow-up reporting by the Journal on Friday, this disagreement had allegedly escalated to the point where Trump signed off on a plan to remove Makary from his position.
When directly asked if he planned to bring in a new FDA head, Trump responded with a definitive “no, no,” contradicting the media reports.
Makary, a former oncology surgeon who was confirmed as FDA Commissioner in March 2025, has found himself at the center of several controversies during his relatively short tenure at the agency. His leadership has created unusual political fault lines that don’t follow traditional partisan divisions.
Pro-life organizations have been particularly vocal in their criticism of Makary, accusing him of deliberately slow-walking a safety review for the abortion pill mifepristone. SBA Pro-Life America president Marjorie Dannenfelser has been among the most outspoken critics, describing the situation as “a five-alarm crisis for the pro-life movement and for the GOP.”
“The GOP cannot win without its base and simply will not get the enthusiasm that drives turnout without leadership from the top,” Dannenfelser said in a statement calling for Makary’s dismissal.
The pharmaceutical and biotechnology industries have also positioned themselves against Makary. John Crowley, head of the Biotechnology Innovation Organization (BIO), criticized Makary’s approach to staffing in a recent op-ed, writing that “some of the administration’s recent efforts to reform the federal government through aggressive and often indiscriminate personnel cuts have lacked the strategic insights necessary to modernize and reform our nation’s health care agencies, especially the FDA.”
However, Makary has found strong supporters among advocates aligned with Health and Human Services Secretary Robert F. Kennedy Jr.’s “Make America Healthy Again” (MAHA) movement. These supporters characterize the calls for his firing as corporate-funded attacks from pharmaceutical interests.
Kelly Ryerson, an author and advocate known as “Glyphosate Girl,” defended Makary in comments to Fox News Digital. “Dr. Makary is an ally in the MAHA movement,” Ryerson said. “It is not surprising that his uncaptured approach to protecting human health has been met with the swamp calling for his firing.”
Similar sentiments were echoed by Turning Point USA-affiliated podcaster Alex Clark, who wrote on social media platform X: “The attacks against FDA Commissioner Marty Makary are coming from Big Pharma and the media outlets financially dependent on pharmaceutical advertising for survival.” Clark added that “Washington SWAMP CREATURES hate Makary because he brings actual scientific scrutiny, independent thinking, and puts Americans’ health FIRST.”
Vani Hari, a prominent food blogger with significant influence in the MAHA movement, also publicly stated that removing Makary “would be a horrible move.”
The conflicting positions illustrate the complex dynamics within the Trump administration, where traditional conservative causes like anti-abortion advocacy have sometimes clashed with the health reform agenda championed by Kennedy and his supporters. The disagreement over flavored vapes represents just one of several contentious health policy issues where these competing priorities have created unusual alliances and divisions.
For now, Makary remains in his position as FDA Commissioner, with President Trump publicly denying any immediate plans for his removal.
Fact Checker
Verify the accuracy of this article using The Disinformation Commission analysis and real-time sources.
16 Comments
Curious to see how this plays out. The FDA commissioner plays a pivotal role, so any shakeup at the top could have far-reaching implications.
Indeed. The FDA’s credibility and public trust are paramount, so this situation bears close monitoring.
Interesting development with the potential removal of the FDA commissioner. I wonder what the underlying reasons are and how it might impact drug approvals and oversight going forward.
Yes, it bears watching closely. Political tensions and disagreements can sometimes overshadow the critical role the FDA plays in public health and safety.
This news about the FDA commissioner raises red flags. The integrity of the agency’s decision-making process needs to be protected, regardless of political pressures.
Exactly. The FDA’s work is too important to be compromised by partisan interests or external influence.
The potential dismissal of the FDA chief raises questions about the administration’s priorities. I hope any changes are made with the utmost care and transparency.
Absolutely. The public deserves to know the reasoning behind any high-level personnel decisions at the FDA.
Given the sensitive nature of the FDA’s work, it’s concerning to see potential political interference. Maintaining the agency’s independence and integrity is crucial.
I agree. The FDA must remain insulated from undue influence to effectively carry out its public health mission.
The potential removal of the FDA chief is concerning, given the agency’s critical role in safeguarding public health. I hope the administration proceeds cautiously.
Agreed. The FDA must remain independent and focused on its core mission, not on political agendas.
I’m curious to learn more about the reasons behind the potential dismissal of the FDA chief. Transparency and accountability are crucial for an agency of such importance.
Agreed. Any changes at the top of the FDA should be accompanied by a clear and thorough explanation to the public.
The FDA plays a vital role in overseeing drug and medical product safety. Any changes at the top need to be approached thoughtfully, with the public’s best interests in mind.
Absolutely. The FDA commissioner should be an impartial, science-based leader, not someone beholden to political pressure.